Clinical trials combining osimertinib and immunotherapy showed intolerable toxicity, and, on the other hand, most clinical trials combining chemo- and immunotherapy lacked a significant number of patients with EGFR mutant NSCLC to draw definitive conclusions on efficacy [15]. Here, EGFR is linked to non-small cell lung carcinoma.